15-min delayed · Sep 4, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Zentalis Pharmaceuticals Llc, 3 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $4.00 to $11.00 (about 2.8x), a sign of real disagreement on valuation. The average target of $8.25 sits 107% above the current $4.00. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 1 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.55 next quarter toward $-1.81 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Moderate Buy
Strong Buy00%
Buy375%
Hold125%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Zentalis Pharmaceuticals Llc.
As of Sep, 3 of 4 firms rate ZNTL a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ZNTL EPS & revenue forecast
EPS · NEXT QUARTER
$-0.55
Range $-0.66 – $-0.35 · 7 analysts · +13% YoY
Next period, 7 analysts expect Zentalis Pharmaceuticals Llc to earn $-0.55 a share (range $-0.66 – $-0.35), versus $-0.49 a year earlier. Full-year consensus is $-2.11, growing to $-1.81 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 7 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $16.4M next year.
Top analysts covering Zentalis Pharmaceuticals Llc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ZNTL.
#1
Michael Schmidt
Guggenheim · Rank #2
Buy
$10.00+150.3% to target
Overall win rate
55%
+ Follow
#2
Andrew Fein
HC Wainwright & Co. · Rank #55
Buy
$10.00+150.3% to target
Overall win rate
46%
+ Follow
#3
Andrew Berens
Leerink Partners · Rank #121
Hold
$5.00+25.2% to target
Overall win rate
56%
+ Follow
#4
Andres Y. Maldonado
HC Wainwright & Co. · Rank #227
Buy
$10.00+150.3% to target
Overall win rate
39%
+ Follow
#5
Matthew Harrison
Morgan Stanley · Rank #300
Hold
$4.00+0.1% to target
Overall win rate
45%
+ Follow
ZNTL stock forecast FAQ
What is ZNTL's average 12-month price target?+
The 3 analysts with a live target average $8.25 for Zentalis Pharmaceuticals Llc over the next 12 months, ranging from a $11.00 high to a $4.00 low.
Is ZNTL stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 4 analyst ratings, 3 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ZNTL?+
The Street-high target is $11.00, and the Street-low is $4.00 (Morgan Stanley). The average of all 3 active targets is $8.25.
How many Wall Street analysts cover ZNTL?+
4 analysts have an active rating on Zentalis Pharmaceuticals Llc, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering ZNTL?+
Among analysts who currently cover ZNTL, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #2). Their current call is Buy with a $10.00 target.
What is Zentalis Pharmaceuticals Llc's projected EPS for next quarter?+
The consensus estimate is $-0.55 per share (range $-0.66 – $-0.35) across 7 analysts. Full-year EPS is projected at $-2.11, rising to $-1.81 the following year.
How much revenue is Zentalis Pharmaceuticals Llc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $16.4M next year.
Have analysts been upgrading or downgrading ZNTL lately?+
As of Sep, 3 of 4 firms rate ZNTL a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ZNTL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
